So yes, there are many good reasons to be cautiously optimistic. Of course the side effects of an untargetted immunosuppresant drug is likely too great for general MPB, but it may lead to further research. As it stands most companies do not do research directly for drugs targetting MPB because past drugs have been market failures.
If MPB were a classical autoimmunity, it would have already been "cured" (as in, an effective treatment protocol would be laid out). Instead, it seems to be some not so subtle side effect of hormonal nuclear war, and scientists have spend decades hunting down the various little side chains to the main problem.
The best hope yet for MPB seems to be PGD2 formation inhibitors or GPR44 antagonists which are still undergoing characterization. But my bet is that like DHT, PGD2 overexpression in scalps is simply yet another side effect of the greater convoluted underlying process, and that treating it directly won't be as effective as promised. (Or worse; GPR44 is implicated in some kinds of asthma as well, which means that a drug that targets the receptor might have a wider spectrum of activity -> worse side effects.)
Can you elaborate on how that is possible? Surely a cure for MPB would be a guaranteed billion dollar product.